Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.
Expert Rev Clin Pharmacol
; 14(10): 1289-1294, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1360277
ABSTRACT
PURPOSE:
We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients.METHODS:
We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our Institution from 20 May 2020 to 20 November 2020 with computer tomography (CT) detected PE at admission, treated with edoxaban after initial parenteral therapy. Clinical outcomes were compared between patients with and without ARDS at admission and between those with and without CT confirmed PE resolution.RESULTS:
50 patients were included. Mean follow-up was 42.5 ± 10 days. No baseline differences were found between patients with ARDS (30%) and those without ARDS at admission. Patients with PE resolution (84%) were younger (P = 0.03), had a shorter duration of fondaparinux therapy (9.9 ± 3.8 vs 15.8 ± 7.5 days; P = 0.0015) and length of hospitalization (36 ± 8 vs 46 ± 9 days P = 0.0023) compared with those without PE resolution. 2 patients experienced major bleedings. At multivariate analysis the time to edoxaban switch was the only predictor of the PE resolution (HR 0.92; 95% C.I. 0.86 to 0.99).CONCLUSION:
Edoxaban was an effective and safe treatment for acute PE in COVID-19 setting.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Embolia Pulmonar
/
Piridinas
/
Tiazoles
/
Inhibidores del Factor Xa
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
/
Middle aged
Idioma:
Inglés
Revista:
Expert Rev Clin Pharmacol
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
17512433.2021.1964359
Similares
MEDLINE
...
LILACS
LIS